ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
| العنوان: | ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases |
|---|---|
| المؤلفون: | Luigi De Petris, Signe Friesland, Simon Ekman, Caroline Kamali, Rolf Lewensohn, Georgios Tsakonas |
| المصدر: | Cancers, Vol 12, Iss 1804, p 1804 (2020) Cancers Volume 12 Issue 7 |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Prognostic variable, Multivariate analysis, overall survival, ALK-Brain Prognostic Index, ALK translocation, lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, brain metastases, medicine, Overall survival, 030212 general & internal medicine, Lung cancer, non-small cell lung cancer, Univariate analysis, Proportional hazards model, business.industry, Retrospective cohort study, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prognostic score, 030220 oncology & carcinogenesis, Non small cell, business |
| الوصف: | Background: Disease-specific Graded Prognostic Assessment (DS-GPA) is the most validated prognostic tool for patients with brain metastasized lung cancer. The Lung-molGPA scoring system was recently introduced for oncogenic-driven brain metastasized lung cancer, but has not yet been validated in cohorts including only ALK-translocated tumors. Methods: We designed a retrospective cohort study consisting of 44 patients with brain metastasized ALK-positive, non-small cell lung cancer (NSCLC) who were treated between January 2009 and November 2019 at Karolinska University Hospital in Stockholm, Sweden. Information about demographics and clinicopathological parameters were collected. Predictors of overall survival (OS) were identified by Cox regression analyses. A bootstrap validation with 1000 samples was performed in order to compare the different prognostic scores. Results: The variables found to independently influence OS in the multivariate analysis, i.e., PS, sex and brain metastases at diagnosis, were used as prognostic variables in our new prognostic index (ALK-BPI). Patients were divided into two prognostic groups. The median OS was 65.7 months for the good prognostic group and 22.7 months for the poor prognostic group (p = 0.0068). In the univariate analysis of the different prognostic scores, ALK-BPI performed better than the others (HR = 3.6 95% CI: 1.3&ndash 9.9). The mean C-statistics of the different prognostic scores were compared to each other, and no significant difference was observed. Conclusion: We propose the ALK-BPI score as a new prognostic tool that can easily be applied for ALK-positive lung cancer patients with brain metastases in daily clinical practice, as it has at least the same prognostic value as Lung-molGPA. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f1d516dac0f175d2278582d376b6cc1 https://www.mdpi.com/2072-6694/12/7/1804 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....0f1d516dac0f175d2278582d376b6cc1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|